These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9537197)

  • 1. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
    Meropol NJ; Blumenson LE; Creaven PJ
    Am J Clin Oncol; 1998 Apr; 21(2):135-8. PubMed ID: 9537197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
    Petrelli NJ; Rodriguez-Bigas M; Rustum Y; Herrera L; Creaven P
    Cancer; 1993 Sep; 72(5):1543-6. PubMed ID: 8348489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
    Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
    Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer.
    Yamaguchi Y; Minami K; Kawabuchi Y; Emi M
    Hepatogastroenterology; 2006; 53(68):201-5. PubMed ID: 16608024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
    Falcone A; Danesi R; Dargenio F; Pfanner E; Brunetti I; Del Tacca M; Nethersell AB; Conte PF
    J Clin Oncol; 1996 Mar; 14(3):729-36. PubMed ID: 8622018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
    Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
    Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
    Chiara S; Nobile MT; Vincenti M; Lionetto R; Gozza A; Barzacchi MC; Sanguineti O; Repetto L; Rosso R
    Cancer Chemother Pharmacol; 1998; 42(4):336-40. PubMed ID: 9744780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
    Yang TS; Wang JY; Tang R; Hsu KC; Chen JS
    Jpn J Clin Oncol; 2002 Sep; 32(9):352-7. PubMed ID: 12417601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
    Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E
    Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
    J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
    Sinnige HA; Buter J; de Vries EG; Uges DR; Roenhorst HW; Verschueren RC; Sleijfer DT; Willemse PH; Mulder NH
    Eur J Cancer; 1993; 29A(12):1715-20. PubMed ID: 8398300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
    Sugano K; Ota K; Taguchi T; Ogawa N; Kurihara M; Akazawa S; Ogawa M; Tominaga T; Sasaki T; Konishi T
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):627-37. PubMed ID: 7717714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.